Acre Aesthetics

Acre Aesthetics is a clinical-stage biotechnology company focused on the development of next-generation neurotoxins for aesthetic and therapeutic applications. The company's lead candidate, ACRE-101, is a novel botulinum toxin type A formulation currently being evaluated in Phase 2 clinical trials for the treatment of moderate to severe glabellar lines. Acre Aesthetics aims to differentiate its products by optimizing clinical performance characteristics, such as duration of effect and onset of action, to better meet the needs of patients and practitioners. By leveraging advanced protein engineering and formulation science, the company seeks to capture a significant share of the rapidly expanding medical aesthetics market. Headquartered in New York, Acre Aesthetics is led by experts in the field of oculofacial plastic surgery and neurotoxin research.